PCSK9 and metabolic syndrome: Commonly prescribed lipid-lowering drugs, such as 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase (HMGCR) inhibitors and proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, play pivotal roles in managing dyslipidemia and reducing cardiovascular risk.